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ABSTRACT
Objective: To examine the basal thyroid function in pediatric Obsessive Compulsive Disor-
der (OCD) versus controls, and to explore the relation between baseline thyroid measures
and response to clomipramine treatment, and the effects of treatment on thyroid hormones.
Methods: Sixteen children and adolescents with DSM-III-R OCE and 13 control children
and adolescents without psychiatric illness were compared on basal measures of thyroid-
stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4). For the OCD subjects,
samples were compared pre- and post- 4 weeks of treatment with clomipramine. Response of
OCD symptoms was measured by the Children’s Yale-Brown Obsessive Compulsive Scale
(CY-BOCS).
Results: OCD subjects demonstrated subtle but significant elevations of TSH, T3, and T4
pre-treatment compared to controls. Clomipramine treatment was associated with significant
decreases in TSH and T3 concentrations. Pre-treatment TSH and T4 concentrations correlated
with reductions in CY-BOCS following 8 weeks of clomipramine.
Conclusion: Elevated thyroid function at baseline may be a biomarker of OCD improve-
ment, and may reflect aspects of the underlying pathophysiology of OCD.
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INTRODUCTION
OBSESSIVE-COMPULSIVE DISORDER (OCD) is achronic, severe neuropsychiatric disorder
with relatively early onset, including for many,
onset of symptoms occurring in childhood or
adolescence (Noshirvani et al. 1991). The fre-
quent association of OCD with symptoms of
depression and anxiety, and responsiveness to
selected antidepressants has led many investi-
gators to examine for possible links between
OCD and a diverse group of depression-re-
lated biological abnormalities. These include
abnormalities suggested to reflect the patho-
physiology of depression and anxiety, for ex-
ample, sleep EEG correlates such as shortened
REM latency, platelet receptor differences, and
hormonal differences, including differences
between adult OCD patients and controls in
the regulation of the hypothalamo-pituitary-
thyroid (HPT) axis. Overall however, thyroid
function in OCD has received scant attention.
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The two available studies do suggest that HPT
function may be altered in patients with OCD.
There are several outstanding questions re-
lating to HPT function and OCD. First, base-
line thyroid function has not been well
characterized in OCD patients. To our knowl-
edge, only two studies have reported detailed
information on thyroid function tests in OCD
patients (Joffe and Swinson 1988; Aizenberg et
al. 1991). These two reports have suggested
normal basal thyroid function tests in adults
with OCD, but one was limited by their use of
depressed adults as the only comparison
group (Joffe and Swinson 1988). However in
the Joffe and Swinson (1988) study, while no
differences in mean triiodothyronine (T3) or
thyroxine (T4) levels were observed, mean
thyroxine (TSH) was elevated in the OCD pa-
tients versus depressives (though skewed by
one patient) with large variability noted. In the
second report, no differences in T3, T4, or
baseline TSH were found for 10 adults with
OCD versus 10 age- and sex-matched normal
controls, but a significant blunting of the TSH
response to thyrotropin releasing hormone
(TRH) was noted for the OCD subjects, with
70% manifesting a blunted response by virtue
of their having a DTSH of <5 mu/ml (Aizen-
berg et al. 1991). Therefore, thyroid function
abnormalities in this small number of OCD pa-
tients were not uncommon. One additional
criticism of the extant data on basal thyroid
status is that both investigations relied upon
the older double antibody radioimmunoassay
method for TSH measurement. Because day-
time TSH concentrations are quite low, it is
possible that subtle patient-control differences
have been obscured by a “floor” effect. The ad-
vent of the new generation of ultrasensitive
immunoradiometric (IRMA) methods for TSH
enables a more accurate comparison of basal
TSH concentrations between OCD patients
and comparison groups.
Second, few biological studies of OCD have
focused on children and adolescents with
OCD, and to our knowledge no studies of ju-
venile OCD subjects have reported on thyroid
status. For biological studies, younger OCD
patients have the theoretical advantages of
having received little or no prior pharmaco-
logic treatment, are less likely to have experi-
enced secondary psychiatric illnesses or physi-
cal illnesses that may have biological sequelae,
and reduce the influence of aging per se on bi-
ological functions.
Lastly, the effects of pharmacologic treat-
ment for OCD on thyroid function and the in-
fluence of initial thyroid function on response
to treatment have not been examined. One
controlled trial of adjunctive T3 versus lithium
administration to a group of adult OCD sub-
jects with a “partial” response to clomipram-
ine treatment was reportedly without effect,
although lithium was noted to reduce depres-
sive symptoms (Pigott et al. 1991). As men-
tioned above, it is not established if OCD
patients are more likely to possess subtle
hypo- or hyperthyroidism, leaving the ratio-
nale for adjunctive T3 administration unclear.
The purpose of the present report was to
further our understanding of the relation be-
tween the HPT axis and OCD by examining
basal HPT measures in a population of chil-
dren and adolescents with OCD versus age-
matched normal controls, and to assess the
influence of 4 weeks of clomipramine treat-
ment on HPT measures.
MATERIALS AND METHODS
Subjects
Portions of the study design and clinical re-
sponse to clomipramine treatment have been
described previously (Hanna et al. 1991). Six-
teen subjects (twelve males, four females) with
OCD diagnosed by DSM-III-R criteria (APA
1987) and thirteen normal control children and
adolescents (seven males, six females) without
a personal lifetime history of any Axis I psy-
chiatric disorder comprised the study sample.
Ages ranged from nine to seventeen years
(mean = 13.6 years) for the OCD subjects.
Normal control subjects ranged in age from
ten to seventeen years (mean= 13.1 years). All
study participants underwent a comprehen-
sive diagnostic assessment consisting of a clin-
ical interview, a structured research diagnostic
interview, and completion of rating scales,
which included (for the OCD subjects only)
the Children’s Yale-Brown Obsessive-Compul-
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sive Scale (CY-BOCS; Goodman and Price
1989), and the NIMH Global Obsessive-Com-
pulsive Scale (GOCS; Murphy et al. 1989). All
OCD subjects scored >16 on the CY-BOCS
(Goodman and Price 1989) and at least seven
on the GOCS at initial assessment. Subjects
meeting criteria for OCD were excluded if any
of the following were present: A 17-item
Hamilton Depression Rating Score (HDRS) of
16 or more, major medical illness, mental re-
tardation, organic mental disorder, pervasive
developmental disorder, psychosis, schizo-
typal personality disorder, bipolar disorder,
panic disorder, agoraphobia, eating disorders,
or suicidal behavior. As above, the normal con-
trols were required to be free of any lifetime
history of Axis I psychiatric disorders. None of
the patients had received any medications
during the 14 days prior to initial blood
sampling.
Following baseline evaluation, all OCD sub-
jects were treated with clomipramine, which
was titrated similarly over three weeks to a
maximum daily dose of 3 mg/kg. At four
weeks of treatment the mean daily dose was
2.67 mg/kg. Response to treatment was as-
sessed by repeat CY-BOCS administration, and
by clinician rating of minimal, moderate, or
good response to treatment as determined by
clinical change at 8 weeks.
Hormone assays
For the OCD subjects, afternoon resting
blood samples were drawn at baseline and
again at four weeks of clomipramine treatment
for hormone measurements. Afternoon blood
samples from the normal controls were also
obtained at rest. Plasma concentrations of total
T3 and total T4 were measured in duplicate by
coated-tube double antibody radioimmunoas-
says (IMMUNOCHEM, ICN Biomedicals, Costa
Mesa, CA). Plasma was analyzed for TSH by
IRMA assay (ICN Biomedicals, Costa Mesa,
CA). Assays were performed by laboratory per-
sonnel blind to subject status and study design.
For T3 and T4, samples were assayed in two
separate batches. All samples were assayed in a
single batch for TSH. For the TSH assay, the
minimal detectable dose is 0.04 mIU/ml, with a
normal range of 0.3–6.5 mIU/ml. Coefficients
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of variation were 4.2, 3.3, and 4.7% for the low,
medium, and high pools, respectively.
Data analysis
Patient-control comparisons were analyzed
by individual unpaired t-tests of independent
means. For analysis of the effects of clomi-
pramine treatment, baseline and 4-week data
from the OCD subjects were analyzed by paired
t-tests. Pearson product-moment correlations
were computed for the thyroid measures. Sta-
tistical significance was set at p < 0.05 for two-
tailed tests.
RESULTS
Age and sex compositions of the two sam-
ples were not significantly different. Compari-
son of the OCD subjects before clomipramine
treatment to normal controls showed the OCD
subjects to demonstrate significantly higher
concentrations for all three thyroid measures.
The OCD subjects showed significantly
greater total T3 concentrations than controls
(OCD vs. control, mean + SEM: 156 + 8.3 vs
117 + 5.0 ng/dl; t = 3.86, p < .0006) (Figure 1).
Similarly, total T4 concentrations were also
greater in the OCD compared to controls
(10.2 + 0.5 vs. 7.7 + 0.34 mg/dl; t = 4.02, p <
0.0004) (Figure 2). TSH was also significantly
greater in the OCD subjects compared to con-
trols (1.49 + .18 vs. .73 + .10 mIU/ml ; t = 3.58;
p<.002) (Figure 3).
Paired t tests between baseline and four
week samples for the OCD subjects revealed a
significant effect of clomipramine treatment
on T3, with T3 concentrations at 4 weeks sig-
nificantly lower than baseline concentrations
(156 + 8.3 vs. 141 + 10.3 ng/dl, t = 2.23, p <
0.05. Similarly, TSH concentrations were sig-
nificantly reduced after 4 weeks of treatment
(1.49 + .18 vs. 1.10 + .11 mIU/ml; t = 2.68, p <
.02). However, paired t-tests failed to show a
significant effect of clomipramine on T4 after
four weeks of treatment (baseline vs. 4 weeks,
10.2 + .5 vs. 10.1 + .11 mg/dl; NS). No signifi-
cant relations were noted between T3, T4, or
TSH hormone concentration and sex, or pres-
ence of washing compulsions.
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Because of our interest in thyroid influences
on clinical response to clomipramine treat-
ment, we also performed exploratory correla-
tional analyses between baseline thyroid
hormone concentrations and symptom mea-
sures after eight weeks of clomipramine. Cor-
relational analysis showed that r= 0.70 (p < .01,
two-tailed) for baseline T4 versus percent re-
duction in CY-BOCS from baseline to eight
weeks of treatment, and r= 0.56 (p < .05, two-
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tailed) for baseline TSH versus percent reduc-
tion in CY-BOCS from baseline to eight weeks
of treatment. Other correlations between T3
and symptom and symptom change measures
were not significant.
DISCUSSION
Although limited by sample size, few hor-
mone measures, and a broad age range, sev-
eral provocative findings of interest emerged
from our pilot study. First, untreated outpa-
tient children and adolescents with OCD com-
pared to normal controls appeared to manifest
subtle but detectable elevations in basal thy-
roid function measures, specifically higher
TSH, total T3, and total T4 concentrations. Sec-
ond, 4 weeks of clomipramine administration
significantly reduced TSH and T3, but not T4
concentrations. Lastly, and of potential rele-
vance to the treatment of OCD, basal T4 and
TSH concentrations before treatment were
possibly associated with the extent of sympto-
matic improvement after 8 weeks of clomi-
pramine treatment.
The findings in our outpatient child and
adolescent OCD sample of increased TSH, T3,
and T4 concentrations compared to normal

















































































* Significantly different versus controls;  p < 0.0006.
FIG. 3.
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normal TSH, T3 and T4 levels in adults with
OCD by Joffe and Swinson (1988) and Aizen-
berg et al. (1991). The reason for such disagree-
ment between our data and prior reports may
rest in the younger age of our sample, the ab-
sence of any prior pharmacologic treatment in
40% of our OCD subjects, exclusion of comor-
bid major depression in our subjects, the tim-
ing of sample collection (afternoon versus
morning samples in the Aizenberg et al.
study), the proportion of females, and assay
methods.
Earlier studies of heterogenous samples of
hospitalized psychiatric patients have re-
ported elevated free thyroxine index (FTI) val-
ues (Cohen and Swigar 1979; Morley and
Shafer 1982; Spratt et al. 1982; Caplan et al.
1983; Chopra et al. 1990), elevated T4 (Spratt et
al. 1982; Morley and Shafer 1982; Chopra et al.
1990), and elevated TSH concentrations (Chopra
et al. 1990). Studies of discrete psychiatric ill-
nesses have yielded different patterns of HPT
function.
The majority of depressed adults have thy-
roid function tests that fall within the normal
range, though decreases versus normals have
been reported (Joffe et al. 1984; Orsulak et al.
1985; Loosen 1987; Prange et al. 1987; Rubin et
al. 1987).
Our finding of elevated T3, T4, and TSH
stands in contrast to the majority, but not all, of
studies of depressed patients by a subtle eleva-
tion, rather than reduction, in HPT status. The
elevation does not appear to be due to altered
peripheral conversion or production of thyroid
hormones. Increased basal HPT status would
provide a mechanism to explain the significant
blunting of the TSH response to TRH in two
adult studies Aizenberg et al. 1991; Lucey et al.
1993. Due to the significant elevation of TSH
versus controls, we conclude that the HPT in-
creases are mediated at a level above the pitu-
itary (presumably associated with chronically
increased TRH secretion) and may involve
neurotransmitters such as serotonin (5-HT),
and perhaps dopamine, both of which have
known effects on HPT function (Tuomisto and
Mannisto 1985), and have also been implicated
in the pathogenesis of OCD (Murphy et al.
1989). It is likely that our use of the ultrasensi-
tive IRMA assay for TSH enabled the detection
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of increased TSH in our OCD sample not seen
in prior reports, in spite of all values falling
within the normal range for TSH.
While some reports have noted decreases in
T3 induced by clomipramine in depressed
adult patients (Schlienger et al. 1981) and in
rats (Massol et al. 1990), to our knowledge this
is the first description of the effects of
clomipramine on thyroid indices in patients
with obsessive-compulsive disorder (OCD).
Our data demonstrated that chronic admin-
istration of clomipramine, an antidepressant
and antiobsessional medication with prominent
effects on serotoninergic neurotransmission, did
produce significant effects on circulating mea-
sures of thyroid function in this sample of chil-
dren and adolescents with OCD. Our findings
largely confirm other reports that have exam-
ined thyroid function changes in depressed
adults receiving antidepressant treatment, in-
cluding clomipramine and desipramine (Schlien-
ger et al. 1980; Brady and Anton 1989). Our
data and those of others is mostly in agree-
ment with animal studies that have noted re-
duced thyroid hormones (Massol et al. 1990)
and TSH (Mueller et al. 1976) following chronic
treatment with tricyclic antidepressants, includ-
ing clomipramine (Massol et al. 1990). How-
ever, these effects are also somewhat selective,
in that a reduction in T3 and TSH was observed
in the absence of a significant change in T4. We
believe that these data, taken together with re-
cent preclinical data and the exploratory corre-
lations between baseline HPT status and
treatment response (see below), have possible
implications for the understanding of the aug-
menting effects of exogenous thyroid hor-
mones in the treatment of depression, and
conversely, for the absence of a therapeutic
benefit of adjunctive T3 in combination with
clomipramine for partially responding patients
with OCD (Pigott et al. 1991).
Interestingly, we observed that both T4 and
TSH concentrations at baseline were highly
correlated with the percent symptom reduction
at 8 weeks of treatment as measured by the
CY-BOCS. While this finding is tempered by a
modest sample size, absence of double-blind
treatment, and not correcting for multiple tests,
it stands in agreement with the notion that ele-
vated HPT status is associated with a greater
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degree of biological dysregulation at a level
above the pituitary, which itself may be related
to the underlying pathophysiology of OCD. 
Although the reciprocal relations between
brain 5-HT systems and the HPT axis are com-
plex, available information suggests that alter-
ations in thyroid status are likely to produce
effects on 5-HT neurotransmission, and con-
versely, that experimental manipulations of 
5-HT can influence HPT measures (Henley et
al. 1991; Sandrini et al. 1991). 
We would propose that treatment-refractory
patients may benefit from interventions that
reduce HPT status, such as propylthiouracil
(PTU). This conclusion is certainly speculative,
but is consistent with the above mentioned
study finding no effect of T3 augmentation of
clomipramine.
CONCLUSION
Taken together, our data and the earlier work
of others on thyroid function in OCD support
the pursuit of larger and more comprehensive
studies of the frequency of HPT axis differ-
ences in OCD patients as well as the relation of
baseline thyroid state to treatment response in
OCD and the effects of antiobsessional agents
on HPT regulation. The fact that significant
differences were observed in children and ado-
lescents with OCD should also strongly en-
courage other studies of younger patients with
the disorder, a group that to date has unfortu-
nately received less attention.
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